Abstract:Epidermal growth factor receptor (EGFR) is the most attractive target for drug research in non-small cell lung cancer (NSCLC). The first-generation EGFR tyrosine kinase inhibitors (TKIs) Gefetinib and Elotinib showed good clinical efficacy on lung adenocarcinoma tumors, but almost all patients developed resistance to these inhibitors over time. Quinazoline and quinoline derivatives are common targeted inhibitors of EGFR kinase, and their structural optimization is an important direction for the development of effective targeted anticancer drugs. Based on these facts, a series of heterocyclic 2,3-dihydro-[1,4]dioxino[2,3-f]quinazoline derivatives have been designed and synthesized and their structures were confirmed by spectral analyses. The cytotoxic activity of the newly synthesized compounds was evaluated against the human kidney epithelial T293 cell line, normal lung cell lines WI-38, non-small cell lung cancer A549 and NCI-H157 cell lines using MTT. The tested compounds showed an evident anticancer activity against the tested cell lines, especially compound 13c, which was the most potent anticancer agent with half maximal inhibitory concentrations (IC50) between 8.82 and 10.24 μM. Docking study showed that compound 13b could be nicely bound to the ATP binding pocket of EGFR. In addition, the inhibitory activity of the target compounds against epidermal growth factor receptor tyrosine kinase (EGFR-TK) was evaluated. Results indicated the ability of the target compounds to inhibit EGFR-TK with half maximal inhibitory concentrations (IC50) in the range of 10.29 nM to 652.3 nM. In view of the reported compound activity, the structure deserves further optimization as cancer treatment agents.

The Design, Synthesis and Biological Evaluation of 7-Alkoxy-4-heteroarylamino-3-cyanoquinolines As Dual Inhibitors of C-Src and Inos.

The Design, Synthesis and Anticancer Activity of 4-Heteroarylamino-3-cyanoquinolines As Dual Inhibitors of C-Src and Inos

Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase.

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, Synthesis, and Evaluation of Substituted 6-Amide-4-anilinoquinazoline Derivatives As C-Src Inhibitors

Design, Synthesis and Biological Evaluation of 6-(Nitroimidazole-1h-alkyloxyl)-4-anilinoquinazolines As Efficient EGFR Inhibitors Exerting Cytotoxic Effects Both under Normoxia and Hypoxia.

Synthesis and in Vitro Anticancer Activity of 6,7-Methylenedioxy (or 5-Hydroxy-6-methoxy)-2-(substituted Selenophenyl)Quinolin-4-One Analogs

Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Synthesis, Molecular Modeling, and Biological Evaluation of Quinazoline Derivatives Containing the 1,3,4-Oxadiazole Scaffold As Novel Inhibitors of VEGFR2

Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives As Novel Inhibitors of VEGFR2.

Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Design, Synthesis and Biological Evaluation of C-Met Kinase Inhibitors Bearing 2-Oxo-1,2-dihydroquinoline Scaffold

Discovery of 4,6-substituted-(diaphenylamino)quinazolines as potent c-Src inhibitors.

Design, Synthesis, and Biological Evaluation of Novel N-γ-carboline Arylsulfonamides As Anticancer Agents.

Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors

Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition

Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.

Design, synthesis and biological evaluation of 2,3-dihydro-[1,4]dioxino[2,3-f]quinazoline derivatives as EGFR inhibitors